# OnCo record paper-lms-04-doxorubicin-trabectedin-lancet-oncol-2022 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-lms-04-doxorubicin-trabectedin-lancet-oncol-2022/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-lms-04-doxorubicin-trabectedin-lancet-oncol-2022" ;
  schema:name "LMS-04: doxorubicin plus trabectedin followed by trabectedin maintenance versus doxorubicin alone in metastatic leiomyosarcoma"@en ;
  schema:description "Combining trabectedin with doxorubicin as first-line treatment for metastatic leiomyosarcoma nearly doubled the time to progression compared with doxorubicin alone, and later showed a survival benefit, making it the first combination to beat single-agent doxorubicin in a sarcoma subtype."@en ;
  schema:url <https://onco.cc/key-papers/paper-lms-04-doxorubicin-trabectedin-lancet-oncol-2022/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S1470-2045(22)00380-1>, <https://pubmed.ncbi.nlm.nih.gov/35835135/> ;
  schema:sameAs <https://doi.org/10.1016/S1470-2045(22)00380-1> ;
  schema:datePublished "2022"^^xsd:gYear ;
  schema:author "Pautier P, Italiano A, Piperno-Neumann S, et al." ;
  onco:cancers <https://onco.cc/cancers/extremity-soft-tissue-sarcoma/>, <https://onco.cc/cancers/leiomyosarcoma/>, <https://onco.cc/cancers/retroperitoneal-sarcoma/> ;
  onco:drugs <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/trabectedin/> ;
  onco:trials <https://onco.cc/trials/lms-04/> ;
  onco:journals <https://onco.cc/journals/lancet-oncology/> .